AKT1 and diabetic kidney disease: For ginsenoside Rh1, activation of the AMPK/PI3K/AKT pathway mediates the inhibition of advanced glycation end product accumulation and inflammatory factor release, explaining its renoprotective effects in diabetic nephropathy (Su et al., 2021).